Category: Tengion Inc.Syndicate content

Tengion's Q2 losses widen

August 20, 2013 by Sony Salzman

Tengion posts greater losses during the 2nd quarter as it develops its human organ transplant technology, but rakes in more than $30M in investments.

Tengion parses losses while ramping up spending

Tengion (NSDQ:TNGN) almost tripled its losses in the 2nd quarter, but raked in more than $30 million in investments for its human organ regeneration technology.

Tengion raises $74M for organ programs

August 7, 2013 by Brad Perriello

Tengion Inc. raises $74.3 million to back its Neo-Kidney Augment and Neo-Urinary Conduit clinical programs.

Tengion raises $74M for organ programs

Tengion (NSDQ:TNGN) said it raised $74.3 million from 22 unnamed investors as it puts a pair of clinical programs through their paces.

The Winston-Salem, N.C.-based medical device company is developing the Neo-Kidney Augment and Neo-Urinary Conduit, human organs that are grown using a bioabsorbable scaffold and patients' own cells.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Tengion soars on raising $34M in support of organ regeneration platform

July 2, 2013 by Arezu Sarvestani

Tengion Inc. raises $33.6 million from a pair of investors supporting its Neo-Kidney Augment and Neo-Urinary Conduit clinical programs.

Tengion logo

North Carolina regenerative medicine company Tengion (NSDQ:TNGN) raised $33.6 million in support of clinical studies of its leading programs, the Neo-Kidney Augment and Neo-Urinary Conduit programs. TNGN shares jumped 15.3% to 68¢ around 12:40 p.m. today, up from an opening price of 64¢.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Tengion issues updates on clinical trial following patient deaths

October 26, 2012 by MassDevice staff

Tengion's clinical trial of its Neo-Urinary Conduit system will continue after 2 of the 6 enrolled patients died from causes unrelated to the trial.

Tengion logo

Tengion (NSDQ:TNGN) plans to complete enrollment its in Neo-Urinary Conduit clinical trial following the deaths of 2 of the 6 enrolled patients after deeming the deaths unrelated to the device or surgical procedure.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Diabetes: Medtronic's Resolute stent performs well in non-diabetics, too | Wall Street Beat

May 25, 2012 by MassDevice staff

Medtronic touts news study results comparing its Resolute drug-eluting stent in patients with and without diabetes; also, Tengion struggles, but may find refuge in Medtronic; Uroplasty soars on 40% boost in Q4 sales; NeuroMetrix targets investors; Allscripts shareholders launch proxy war; plus, a Funding Roundup and analysts' ups and downs.

MassDevice.com Wall Street Beat

Medtronic (NYSE:MDT) touted new study results for its Resolute drug-eluting stents, the 1st with FDA indication for treatment of patients with diabetes.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Abbott wins FDA nod for next-gen cataract laser | Regulatory Roundup

April 20, 2012 by MassDevice staff

Abbott gets FDA nod for advanced femtosecond laser for cataract surgery, St. Jude Medical launches next-gen Trifecta heart valve in Japan, NeuroMetrix files 510(k) for Sensus neurostimulator for pain management, and more.

MassDevice.com Regulatory Roundup

 Abbott gets FDA nod for advanced femtosecond laser for cataract surgery

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp